Periodontitis, Smoking
Conditions
Keywords
non surgical periodontal therapy, smoking, periostin, IL-17, gingival crevicular fluid
Brief summary
It was aimed to evaluate the changes in the levels of Periostin, IL-17A and IL-17E cytokines in the gingival crevicular fluid (GCF) of periodontitis patients which non-surgical (Phase I) periodontal treatment applied to and their interactions with smoking. The study included systemic healthy smokers(SP)(n:11) and non-smokers(P)(n:11) with periodontitis, smokers (SS)(n:11) and non-smokers(S)(n:11) with periodontal healthy individuals Phase I periodontal treatment was applied to the groups with periodontitis. Before treatment (day 0), clinical measurements evaluating periodontal status were recorded and GCF samples were collected. GCF samples were collected from the same tooth regions on the 15th and 30th days after treatment and clinical measurements were repeated. GCF Periostin, IL-17A and IL-17E levels were determined by ELISA method. All data were evaluated statistically.
Detailed description
The SH and H groups' patients were instructed to visit for routine controls without receiving any periodontal treatment. However, after the GCF sampling, patients in the SP and P groups received Non-surgical periodontal treatment(NSPT) included detailed oral hygiene instruction and reinforcement in conjunction with scaling and root planning as a full mouth debridement protocol in a single session They were instructed to refrain from using any chemicals, including mouthwash, to remove plaque. The periodontitis patients received a follow-up call on the 15th and 30th days following treatment. The GCF sampling procedure was first repeated on the teeth from which a previous GCF sample had been taken. Then, values for the clinical examination parameters (PI, GI, BOP, PD, and CAL) were once again measured and recorded. Daily plaque care efficacy or deficiency was checked and/or reinforced at every recall. All these procedures were performed by a single investigator.
Interventions
Phase 1 periodontal (full mouth debridement) treatment was applied to groups with periodontitis in one session.
Sponsors
Study design
Intervention model description
The study included systemic healthy smokers(SP)(n:11) and non-smokers(P)(n:11) with periodontitis, smokers (SH)(n:11) and non-smokers(H)(n:11) with periodontal healthy individuals
Eligibility
Inclusion criteria
* generalized stage 3 periodontitis or periodontally healthy; * smoker ((≥10 cigarettes/day for \>5 years) or nonsmoker (never smoked in their lifetime); * not have received any periodontal treatment in the last 6 months, took any antibiotics, anti-inflammatory drugs regularly and for female subjects, not to be pregnant, lactating, or menopause.
Exclusion criteria
* Under 18 years of age * Those with a systemic disease * Cancer patients, those with a history of chemotherapy and radiotherapy * Pregnant and breastfeeding women * Those who smoke less than 10 cigarettes a day and those who quit smoking * Having received orthodontic treatment in the last 6 months * Using antibiotics, anti-inflammatory or any medication in the last 6 months * Those who do not consent voluntarily
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of Periostin levels | 0-15-30 days | The effect of non-surgical periodontal treatment in gingival crevicular fluid periostin levels |
| Evaluation of IL-17A levels | 0-15-30 days | The effect of non-surgical periodontal treatment in gingival crevicular fluid IL-17A levels |
| Evaluation of IL-17E levels | 0-15-30 days | The effect of non-surgical periodontal treatment in gingival crevicular fluid IL-17E levels |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Interaction Between Smoking and GCF Periostin, IL17A, IL17E levels | 0-15-30 days | Comparisons between groups were made to evaluate the effect of smoking on non-surgical periodontal treatment. |
Countries
Turkey (Türkiye)